Culine S, Abs L, Terrier-Lacombe M J, Théodore C, Wibault P, Droz J P
Department of Medicine, Institut Gustave Roussy, Villejuif, France.
Eur J Cancer. 1998 Feb;34(3):353-8. doi: 10.1016/s0959-8049(97)10070-3.
The aim of this study was to report the results of cisplatin-based combination chemotherapy for patients with pure seminomatous tumours. 72 patients with advanced seminoma were treated with various cisplatin-based chemotherapy regimens. 61 (85%) patients achieved a sustained durable response. 11 relapses were observed with a median time to failure of 6 months. Overall, 60 (83%) of the 72 patients remain alive and free of disease after a median follow-up of 64 months. Initial clinical (age, site of primary, prior radiotherapy, extent of disease) and biological (serum human chorionic gonadotrophin levels, serum lactic dehydrogenase levels, p53 immunostaining) features which could be of predictive value for survival, were analysed in a univariate analysis. No variable retained statistical significance. High cure rates are expected after chemotherapy with standard cisplatin-based combinations in advanced seminoma. Renewed efforts are required to identify markers of chemosensitivity.
本研究的目的是报告基于顺铂的联合化疗治疗纯精原细胞瘤患者的结果。72例晚期精原细胞瘤患者接受了各种基于顺铂的化疗方案。61例（85%）患者获得了持续的持久缓解。观察到11例复发，中位失败时间为6个月。总体而言，72例患者中有60例（83%）在中位随访64个月后仍存活且无疾病。在单因素分析中，对可能具有生存预测价值的初始临床（年龄、原发部位、既往放疗、疾病范围）和生物学（血清人绒毛膜促性腺激素水平、血清乳酸脱氢酶水平、p53免疫染色）特征进行了分析。没有变量具有统计学意义。晚期精原细胞瘤采用标准的基于顺铂的联合化疗后有望获得高治愈率。需要重新努力寻找化疗敏感性标志物。
